Details
Stereochemistry | ACHIRAL |
Molecular Formula | C8H10N4O2 |
Molecular Weight | 194.1906 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C=NC2=C1C(=O)N(C)C(=O)N2C
InChI
InChIKey=RYYVLZVUVIJVGH-UHFFFAOYSA-N
InChI=1S/C8H10N4O2/c1-10-4-9-6-5(10)7(13)12(3)8(14)11(6)2/h4H,1-3H3
DescriptionSources: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C328Curator's Comment: description was created based on several sources, including
http://www.webmd.com/vitamins-supplements/ingredientmono-979-caffeine.aspx?activeingredientid=979
Sources: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C328
Curator's Comment: description was created based on several sources, including
http://www.webmd.com/vitamins-supplements/ingredientmono-979-caffeine.aspx?activeingredientid=979
Caffeine is a methylxanthine alkaloid found in the seeds, nuts, or leaves of a number of plants native to South America and East Asia that is structurally related to adenosine and acts primarily as an adenosine receptor antagonist with psychotropic and anti-inflammatory activities. Upon ingestion, caffeine binds to adenosine receptors in the central nervous system (CNS), which inhibits adenosine binding. This inhibits the adenosine-mediated downregulation of CNS activity; thus, stimulating the activity of the medullary, vagal, vasomotor, and respiratory centers in the brain. The anti-inflammatory effects of caffeine are due the nonselective competitive inhibition of phosphodiesterases.
Caffeine is used by mouth or rectally in combination with painkillers (such as aspirin and acetaminophen) and a chemical called ergotamine for treating migraineheadaches. It is also used with painkillers for simple headaches and preventing and treating headaches after epidural anesthesia. Caffeine creams are applied to the skin to reduce redness and itching in dermatitis. Healthcare providers sometimes give caffeine intravenously (by IV) for headache after epidural anesthesia, breathing problems in newborns, and to increase urine flow. In foods, caffeine is used as an ingredient in soft drinks, energy drinks, and other beverages.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL251 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24164628 |
23.4 µM [Ki] | ||
Target ID: CHEMBL255 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24164628 |
20.5 µM [Ki] | ||
Target ID: CHEMBL226 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24164628 |
44.9 µM [Ki] | ||
Target ID: CHEMBL2111322 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2374150 |
70.0 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.drugs.com/pro/cafergot.html |
Primary | CAFERGOT Approved UseErgotamine is an alpha adrenergic blocking agent with a direct stimulating effect on the smooth muscle of peripheral and cranial blood vessels and produces depression of central vasomotor centers. The compound also has the properties of serotonin antagonism. In comparison to hydrogenated ergotamine, the adrenergic blocking actions are less pronounced and vasoconstrictive actions are greater. Caffeine, also a cranial vasoconstrictor, is added to further enhance the vasoconstrictive effect without the necessity of increasing ergotamine dosage. Launch Date1948 |
||
Primary | CAFCIT Approved UseCaffeine Citrate injection USP is indicated for the short-term treatment of apnea of prematurity in infants between 28 and <33 weeks gestational age. Launch Date1999 |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.35 μg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28561231 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
CAFFEINE unknown | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
65.64 μg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28561231 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
CAFFEINE unknown | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
43000 nM*h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01361217 |
100 mg single, oral dose: 100 mg route of administration: oral experiment type: single co-administered: |
CAFFEINE plasma | Homo sapiens population: healthy age: adults sex: food status: |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10.19 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28561231 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
CAFFEINE unknown | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
12.4 g single, oral Overdose |
unknown, 14 years n = 1 Health Status: unknown Age Group: 14 years Sex: F Population Size: 1 Sources: |
Other AEs: Nausea, Vomiting... |
50 g single, oral Overdose |
unknown, 27 years n = 1 Health Status: unknown Age Group: 27 years Sex: F Population Size: 1 Sources: |
Other AEs: Tachycardia, Seizure... Other AEs: Tachycardia (1 patient) Sources: Seizure (1 patient) |
5000 mg single, oral (total) Overdose |
healthy, 32 years n = 1 Health Status: healthy Age Group: 32 years Sex: F Population Size: 1 Sources: |
Other AEs: Malaise, Anxiety... Other AEs: Malaise (1 patient) Sources: Anxiety (1 patient) Dizziness (1 patient) Nausea (1 patient) |
4000 mg single, oral Overdose |
pregnant, 33 years n = 1 Health Status: pregnant Age Group: 33 years Sex: F Population Size: 1 Sources: |
Other AEs: Nausea, Vomiting... |
1.6 g single, oral Overdose |
healthy, 44 years n = 1 Health Status: healthy Age Group: 44 years Sex: M Population Size: 1 Sources: |
Other AEs: Atrial fibrillation... |
800 mg multiple, oral (total) Highest studied dose |
healthy, adult n = 12 Health Status: healthy Age Group: adult Population Size: 12 Sources: |
|
24 g single, oral Overdose |
unknown, adult n = 1 Health Status: unknown Age Group: adult Sex: M Population Size: 1 Sources: |
Other AEs: Rhabdomyolysis, Acute renal failure... Other AEs: Rhabdomyolysis (1 patient) Sources: Acute renal failure (1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Nausea | 1 patient | 12.4 g single, oral Overdose |
unknown, 14 years n = 1 Health Status: unknown Age Group: 14 years Sex: F Population Size: 1 Sources: |
Vomiting | 1 patient | 12.4 g single, oral Overdose |
unknown, 14 years n = 1 Health Status: unknown Age Group: 14 years Sex: F Population Size: 1 Sources: |
Seizure | 1 patient | 50 g single, oral Overdose |
unknown, 27 years n = 1 Health Status: unknown Age Group: 27 years Sex: F Population Size: 1 Sources: |
Tachycardia | 1 patient | 50 g single, oral Overdose |
unknown, 27 years n = 1 Health Status: unknown Age Group: 27 years Sex: F Population Size: 1 Sources: |
Anxiety | 1 patient | 5000 mg single, oral (total) Overdose |
healthy, 32 years n = 1 Health Status: healthy Age Group: 32 years Sex: F Population Size: 1 Sources: |
Dizziness | 1 patient | 5000 mg single, oral (total) Overdose |
healthy, 32 years n = 1 Health Status: healthy Age Group: 32 years Sex: F Population Size: 1 Sources: |
Malaise | 1 patient | 5000 mg single, oral (total) Overdose |
healthy, 32 years n = 1 Health Status: healthy Age Group: 32 years Sex: F Population Size: 1 Sources: |
Nausea | 1 patient | 5000 mg single, oral (total) Overdose |
healthy, 32 years n = 1 Health Status: healthy Age Group: 32 years Sex: F Population Size: 1 Sources: |
Nausea | 1 patient | 4000 mg single, oral Overdose |
pregnant, 33 years n = 1 Health Status: pregnant Age Group: 33 years Sex: F Population Size: 1 Sources: |
Vomiting | 1 patient | 4000 mg single, oral Overdose |
pregnant, 33 years n = 1 Health Status: pregnant Age Group: 33 years Sex: F Population Size: 1 Sources: |
Atrial fibrillation | 1 patient | 1.6 g single, oral Overdose |
healthy, 44 years n = 1 Health Status: healthy Age Group: 44 years Sex: M Population Size: 1 Sources: |
Acute renal failure | 1 patient | 24 g single, oral Overdose |
unknown, adult n = 1 Health Status: unknown Age Group: adult Sex: M Population Size: 1 Sources: |
Rhabdomyolysis | 1 patient | 24 g single, oral Overdose |
unknown, adult n = 1 Health Status: unknown Age Group: adult Sex: M Population Size: 1 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | weak (co-administration study) Comment: When caffeine was coadministered the Cmax of melatonin was increased on average by 137% and AUC by 120% |
|||
Sources: https://pubmed.ncbi.nlm.nih.gov/8723732/ |
yes | |||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 7.0 |
major | likely (co-administration study) Comment: lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin) Page: 7.0 |
||
yes | ||||
yes | ||||
yes | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/8204093/ Page: 9.0 |
yes | |||
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Preparation and primary evaluation of [11C]CSC as a possible tracer for mapping adenosine A2A receptors by PET. | 1999 May |
|
Pharmaceutical cost savings of treating obesity with weight loss medications. | 1999 Nov |
|
Binding of [3H]MSX-2 (3-(3-hydroxypropyl)-7-methyl-8-(m-methoxystyryl)-1-propargylxanthine) to rat striatal membranes--a new, selective antagonist radioligand for A(2A) adenosine receptors. | 2000 |
|
Methadone, ciprofloxacin, and adverse drug reactions. | 2000 Dec 16 |
|
Contribution of ryanodine receptor subtype 3 to ca2+ responses in Ca2+-overloaded cultured rat portal vein myocytes. | 2001 Apr 6 |
|
Ionomycin and 2,5'-di(tertbutyl)-1,4,-benzohydroquinone elicit Ca2+-induced Ca2+ release from intracellular pools in Physarum polycephalum. | 2001 Feb |
|
Age, fatigue, and excitation-contraction coupling in masseter muscles of rats. | 2001 Feb |
|
Adenoviral SERCA1a gene transfer to adult rat ventricular myocytes induces physiological changes in calcium handling. | 2001 Feb 1 |
|
Effects of alprazolam, caffeine, and zolpidem in humans trained to discriminate triazolam from placebo. | 2001 Feb 1 |
|
Evidence for glutamate receptor mediated transmission at mechanoreceptors in the skin. | 2001 Feb 12 |
|
Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. | 2001 Feb 15 |
|
The plant isoflavenoid genistein activates p53 and Chk2 in an ATM-dependent manner. | 2001 Feb 16 |
|
The Haemophilus ducreyi cytolethal distending toxin induces cell cycle arrest and apoptosis via the DNA damage checkpoint pathways. | 2001 Feb 16 |
|
Mechanisms of hydrogen peroxide-induced relaxation in rabbit mesenteric small artery. | 2001 Feb 2 |
|
Caffeine increases paragigantocellularis neuronal firing rate and induces withdrawal signs in morphine-dependent rats. | 2001 Feb 2 |
|
Overexpression of FK506-binding protein FKBP12.6 in cardiomyocytes reduces ryanodine receptor-mediated Ca(2+) leak from the sarcoplasmic reticulum and increases contractility. | 2001 Feb 2 |
|
[Cerebral infarction in a patient consuming MaHuang extract and guarana]. | 2001 Feb 3 |
|
Risk factors for sleep bruxism in the general population. | 2001 Jan |
|
Calculation of the dimensions of dosage forms with release controlled by diffusion for in vivo use. | 2001 Jan |
|
Number of K(Ca) channels underlying spontaneous miniature outward currents (SMOCs) in mudpuppy cardiac neurons. | 2001 Jan |
|
The associations of maternal caffeine consumption and nausea with spontaneous abortion. | 2001 Jan |
|
The effects of phosphodiesterase inhibition on cyclic GMP and cyclic AMP accumulation in the hippocampus of the rat. | 2001 Jan 12 |
|
Functional analysis of the Neurospora crassa PZL-1 protein phosphatase by expression in budding and fission yeast. | 2001 Jan 30 |
|
Fanconi anemia lymphocytes: effect of DL-alpha-tocopherol (Vitamin E) on chromatid breaks and on G2 repair efficiency. | 2001 Jan 5 |
|
Acute but not chronic caffeine impairs functional responses to ischaemia-reperfusion in rat isolated perfused heart. | 2001 Jan-Feb |
|
Adenosine induces initial hypoxic-ischemic depression of synaptic transmission in the rat hippocampus in vivo. | 2001 Mar |
|
Dopaminergic role in stimulant-induced wakefulness. | 2001 Mar 1 |
|
Study of the cytolethal distending toxin (CDT)-activated cell cycle checkpoint. Involvement of the CHK2 kinase. | 2001 Mar 2 |
Patents
Sample Use Guides
Caffeine is used by mouth in combination with painkillers (such as aspirin and acetaminophen) for treating headaches. Maximum oral dose of excedrin is 2 tablets a day (each tablet of excedrin contains 65 mg of caffeine). Caffeine creams are applied to the skin to reduce redness and itching in dermatitis. Healthcare providers sometimes give caffeine intravenously (by IV) for headache after epidural anesthesia, breathing problems in newborns, and to increase urine flow. In foods, caffeine is used as an ingredient in soft drinks, energy drinks, and other beverages.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6309393
Binding of caffeine to adrenergic receptors was measured using [3H]N6-Cyclohexyladenosine as a radioligand. Nonspecificbinding was less than 10% of total binding as defined with 10 uM 2-chloroadenosine. Membranes were incubated with 10-6 - 10-3 M caffeine.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QV04CG30
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
||
|
NDF-RT |
N0000175729
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
||
|
CFR |
21 CFR 340.10
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
||
|
NDF-RT |
N0000175790
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
||
|
WHO-VATC |
QN06BC01
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
||
|
NCI_THESAURUS |
C54060
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
||
|
NCI_THESAURUS |
C47795
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
||
|
NDF-RT |
N0000175739
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
||
|
IARC | Caffeine | ||
|
NDF-RT |
N0000008118
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
||
|
NDF-RT |
N0000008118
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
||
|
DSLD |
367 (Number of products:3156)
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
||
|
FDA ORPHAN DRUG |
367512
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
||
|
EPA PESTICIDE CODE |
660
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
||
|
WHO-ATC |
V04CG30
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
||
|
FDA ORPHAN DRUG |
31288
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
||
|
WHO-ATC |
N06BC01
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
||
|
LIVERTOX |
NBK559835
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
||
|
CFR |
21 CFR 340.50
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Caffeine
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
PRIMARY | |||
|
D002110
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
PRIMARY | |||
|
1886
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
PRIMARY | RxNorm | ||
|
3G6A5W338E
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
PRIMARY | |||
|
407
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
PRIMARY | |||
|
CAFFEINE
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
PRIMARY | Description: Silky, colourless crystals or a white, crystalline powder; odourless. Solubility: Soluble in 60 parts of water and in 100 parts of ethanol (~750 g/l) TS; slightly soluble in ether R. Category: Central nervous stimulant. Storage: Caffeine should be kept in a well-closed container. Labelling: The designation on the container of Caffeine should state whether the substance is the monohydrate or is in the anhydrous form. Additional information: Caffeine monohydrate is efflorescent in air. Definition: Caffeine contains not less than 98.5% and not more than 101.0% of C8H10N4O2, calculated with reference to the dried substance. | ||
|
463
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
PRIMARY | |||
|
1086006
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
ALTERNATIVE | |||
|
DB00201
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
PRIMARY | |||
|
CHEMBL113
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
PRIMARY | |||
|
35
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
PRIMARY | |||
|
2519
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
PRIMARY | |||
|
CAFFEINE
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
PRIMARY | |||
|
1085003
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
PRIMARY | |||
|
C328
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
PRIMARY | |||
|
DTXSID0020232
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
PRIMARY | |||
|
27732
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
PRIMARY | |||
|
SUB26077
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
PRIMARY | |||
|
200-362-1
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
PRIMARY | |||
|
5036
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
PRIMARY | |||
|
347
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
PRIMARY | |||
|
SUB13146MIG
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
PRIMARY | |||
|
58-08-2
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
PRIMARY | |||
|
m2909
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
PRIMARY | Merck Index | ||
|
3G6A5W338E
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
PRIMARY | |||
|
100000089693
Created by
admin on Fri Dec 15 15:20:53 GMT 2023 , Edited by admin on Fri Dec 15 15:20:53 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE ACTIVE (PARENT)
METABOLITE ACTIVE (PARENT)
PARENT (METABOLITE ACTIVE)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)